Charles River Laboratories International, Inc. (CRL) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 55
- Profitability 60
- Business Quality 60
- Balance Sheet 40
- Cash Flow 80
Why this rating?
Health 57/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Charles River Laboratories International, Inc. (CRL) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Charles River Laboratories International, Inc. 57/100 (Acceptable) due to solid business quality, elevated leverage, and fair valuation.
Investment profile
- Quality Moderate
- Growth Soft
- Balance Sheet Stretched
- Valuation Fair
Financial highlights
Valuation
- Forward P/E 28.15
- PEG 0.12
- EV/Revenue 5.01
Profitability
- Revenue Growth -2.7%
- Gross Margin 34.6%
- Operating Margin 15.1%
- Net Margin -6.0%
- ROE -7.5%
Financial strength
- Cash $192.02M
- Debt $3.03B
- Net Cash $-2.84B
- Free Cash Flow $518.49M
- Current Ratio 1.35
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$50.28 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Illumina, Inc. Diagnostics & Research ILMN$279.47 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$70.53 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$50.17 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$232.00 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$242.56 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Sotera Health Company Diagnostics & Research SHC$18.49 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$161.86 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Charles River Laboratories International, Inc. (CRL).